CRISPR/Cas9 Genome Editing in LGMD2A/R1 Patient-Derived Induced Pluripotent Stem and Skeletal Muscle Progenitor Cells

被引:1
|
作者
Mavrommatis, Lampros [1 ,2 ,3 ]
Zaben, Abdul [1 ,2 ]
Kindler, Urs [1 ]
Kienitz, Marie-Cecile [4 ]
Dietz, Julienne [2 ,5 ]
Jeong, Hyun-Woo [6 ]
Boehme, Pierre [7 ]
Brand-Saberi, Beate [1 ]
Vorgerd, Matthias [2 ]
Zaehres, Holm [1 ,3 ]
机构
[1] Ruhr Univ Bochum, Inst Anat, Med Fac, Dept Anat & Mol Embryol, D-44801 Bochum, Germany
[2] Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Dept Neurol, Med Fac,Heimer Inst Muscle Res, D-44789 Bochum, Germany
[3] Max Planck Inst Mol Biomed, Dept Cell & Dev Biol, D-48149 Munster, Germany
[4] Ruhr Univ Bochum, Med Fac, Dept Cellular Physiol, D-44801 Bochum, Germany
[5] Witten Herdecke Univ, Fac Hlth, Dept Human Med, Inst Virol & Microbiol, D-58453 Witten, Germany
[6] Max Planck Inst Mol Genet, Sequencing Core Facil, D-48149 Munster, Germany
[7] Ruhr Univ Bochum, LWL Univ Hosp Bochum, Dept Psychiat Psychotherapy & Prevent Med, D-44791 Bochum, Germany
关键词
GIRDLE MUSCULAR-DYSTROPHY; KAPPA-B PATHWAY; IN-VIVO; PIGGYBAC TRANSPOSASE; MYOGENIC PROGENITORS; PROTEOLYTIC ACTIVITY; GENE-EXPRESSION; SATELLITE CELLS; CALPAIN; MUTATIONS;
D O I
10.1155/2023/9246825
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Large numbers of Calpain 3 (CAPN3) mutations cause recessive forms of limb-girdle muscular dystrophy (LGMD2A/LGMDR1) with selective atrophy of the proximal limb muscles. We have generated induced pluripotent stem cells (iPSC) from a patient with two mutations in exon 3 and exon 4 at the calpain 3 locus (W130C, 550delA). Two different strategies to rescue these mutations are devised: (i) on the level of LGMD2A-iPSC, we combined CRISPR/Cas9 genome targeting with a FACS and Tet transactivator-based biallelic selection strategy, which resulted in a new functional chimeric exon 3-4 without the two CAPN3 mutations. (ii) On the level of LGMD2A-iPSC-derived CD82+/Pax7+ myogenic progenitor cells, we demonstrate CRISPR/Cas9 mediated rescue of the highly prevalent exon 4 CAPN3 mutation. The first strategy specifically provides isogenic LGMD2A corrected iPSC for disease modelling, and the second strategy can be further elaborated for potential translational approaches.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Generation and Characterization of CPVT1 Cardiomyocytes using Human Induced Pluripotent Stem Cells and CRISPR/Cas9 Gene Editing
    Yamaguchi, Naohiro
    Zhang, Xiao-Hua
    Wei, Hua
    Morad, Martin
    BIOPHYSICAL JOURNAL, 2018, 114 (03) : 116A - 116A
  • [42] MODELING AUTISM USING CRISPR/CAS9 AND HUMAN INDUCED PLURIPOTENT STEM CELLS
    Deneault, Eric
    Zaslaysky, Kirill
    Thompson, Tadeo
    Ellis, James
    Scherer, Stephen
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S161 - S161
  • [43] Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells
    Cromer, M. Kyle
    Barsan, Valentin V.
    Jaeger, Erich
    Wang, Mengchi
    Hampton, Jessica P.
    Chen, Feng
    Kennedy, Drew
    Xiao, Jenny
    Khrebtukova, Irina
    Granat, Ana
    Truong, Tiffany
    Porteus, Matthew H.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [44] Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells
    M. Kyle Cromer
    Valentin V. Barsan
    Erich Jaeger
    Mengchi Wang
    Jessica P. Hampton
    Feng Chen
    Drew Kennedy
    Jenny Xiao
    Irina Khrebtukova
    Ana Granat
    Tiffany Truong
    Matthew H. Porteus
    Nature Communications, 13
  • [45] Highly Efficient CRISPR/Cas9-Mediated Genome Editing in Human Pluripotent Stem Cells
    Maguire, Jean Ann
    Gadue, Paul
    French, Deborah L.
    CURRENT PROTOCOLS, 2022, 2 (11):
  • [46] CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells
    Kim, Eun Ji
    Kang, Ki Ho
    Ju, Ji Hyeon
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (01): : 42 - 61
  • [47] Improvement of the knock-in efficiency in the genome of human induced pluripotent stem cells using the CRISPR/Cas9 system
    Gridina, M. M.
    VAVILOVSKII ZHURNAL GENETIKI I SELEKTSII, 2018, 22 (08): : 1026 - 1032
  • [48] AAV9-CRiSPR/Cas9 preclinical trial on patient-derived FOXG1 mutated cells
    Croci, S.
    Daga, S.
    Lorenzetti, F. C.
    Papa, F. T.
    Donati, F.
    Lo Rizzo, C.
    Lopergolo, D.
    Pancrazi, L.
    Doria, M.
    Auricchio, A.
    Costa, M.
    Conticello, S.
    Renieri, A.
    Meloni, I.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 853 - 853
  • [49] Generation of a NONO homozygous knockout human induced pluripotent stem cell line by CRISPR/Cas9 editing
    Yi, Tong
    Bai, Rui
    Sun, Hairui
    Lan, Feng
    Zhang, Hongjia
    He, Yihua
    STEM CELL RESEARCH, 2020, 47
  • [50] An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool
    Javaid, Nasir
    Choi, Sangdun
    STEM CELLS INTERNATIONAL, 2022, 2022